An interventional study of Intermittent Pneumatic Compression and geko® T3 in Ischaemic Stroke, sponsored by Firstkind Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Firstkind Ltd (part of Sky Medical Technology) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Ischemic Stroke with a site in United Kingdom — 14 open to participants now, 20 under way, 5 of them phase 3. Ischemic Stroke · United Kingdom.
Among the 89 studies in Ischemic Stroke with a site in United Kingdom, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 22 with no phase, and was the 87th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →14 of the 89 studies in Ischemic Stroke with a site in United Kingdom are open now. Recruiting first, the newest first:
University Hospitals Coventry and Warwickshire NHS Trust · Sites in United Kingdom
Ages 18+
Takeda · Sites in United Kingdom, United States, Belgium and 7 more countries
Ages 18+
Pharmazz, Inc. · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–80
Corxel Pharmaceuticals · Sites in United Kingdom, United States, Belgium and 18 more countries
Ages 18–90
University of L'Aquila · Sites in United Kingdom, Croatia, Denmark and 12 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 13 · Phase 4 2
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 464 across the 55 interventional studies, 430 across the 34 observational. Of the 55 that completed or were terminated, 17 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Firstkind Ltd, one of the names counted as Sky Medical Technology. Under that name alone:
Firstkind Ltd is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Sky Medical Technology has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Ischemic Stroke with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07943065University Hospitals Coventry and Warwickshire NHS TrustA Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke Patients | 2027-01 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 89 studies in Ischemic Stroke with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care.
The geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow.
The primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).
This study is a randomised trial at a single centre, comparing brain blood flow and activity patterns when two standard treatments for preventing blood clots (VTE) are used following a stroke.
Who Can Take Part?
Patients will be identified for the study as part of their routine hospital care when they arrive at hospital through the emergency department. To take part they must:
What Will Happen?
After confirming eligibility and once consent is given, 80 participants will be randomly assigned to one of two groups during the study period:
Group 1 - IPC device Group 2 - geko® device
Both devices are standard treatments for preventing blood clots.
Study Assessments
Brain blood flow will be measured while participants are sitting upright in bed. Each session will include:
5 minutes with the device switched off 5 minutes with the device switched on
These assessments will take place twice a day for two days (a total of 40 minutes) with a pre-assessment preparation (a total of 80 minutes over the two days). Blood pressure, ECG, temperature, and oxygen levels will be continuously monitored. No follow-up is required after the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for the use of the geko™ device
Contraindications to IPC
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IPC sleeves applied bilaterally according to manufacturer's instructions for standard VTE prophylaxis following ischaemic stroke.
Device: Intermittent Pneumatic Compression
The geko® device is a disposable, battery-powered neuromuscular electrostimulation device applied bilaterally to the peroneal nerve at the knee. It delivers low-frequency stimulation to activate the calf and foot muscle pumps, enhancing venous return and microcirculatory blood flow. Devices will be applied according to the manufacturer's instructions for VTE prophylaxis.
Device: geko® T3
The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.
Also known as: Kendall SCD™ 700 Sequential Compression System
The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.
Also known as: geko® device, neuromuscular electrostimulation
Change in Cerebral Blood Flow During Device Use
Cerebral blood flow (CBF) will be assessed using functional near-infrared spectroscopy (fNIRS) combined with EEG, beat-to-beat blood pressure, and transcutaneous CO₂ monitoring. Measurements will compare baseline (no device) to during active use of either the Intermittent Pneumatic Compression (IPC) device or the geko® T3 device. The primary analysis will evaluate differences in cerebral haemodynamics between the two randomized intervention groups.
Time frame: Day 1-2 (within 36 hours of stroke onset; measurements taken twice daily for 2 consecutive days)
Change in Neurovascular Coupling During Device Use
Changes in neurovascular coupling will be assessed using combined functional near-infrared spectroscopy (fNIRS) and EEG during resting state and during active use of the Intermittent Pneumatic Compression (IPC) device or the geko® T3 device.
Time frame: Day 1-2 (twice daily assessments for 2 consecutive days)
Change in Dynamic Cortical Connectivity During Device Use
Functional connectivity between cortical regions will be measured using fNIRS+EEG data during intervention (IPC or geko® device) compared to baseline.
Time frame: Day 1-2 (twice daily assessments for 2 consecutive days)
Incidence of Adverse Events
Number and type of adverse events observed in participants during and after use of either device.
Time frame: Up to 2 days from enrolment
Incidence of Serious Adverse Events
Frequency of serious adverse events, including death, life-threatening illness, permanent impairment, or prolonged hospitalisation
Time frame: Up to 2 days from enrolment
Incidence of Adverse Device Effects
Frequency of device-related adverse events such as discomfort, skin irritation, or unexpected physiological responses to device use.
Time frame: Up to 2 days from enrolment
Incidence of Serious Adverse Device Effects
Frequency of serious device-related adverse events meeting criteria for seriousness under ISO 14155:2020.
Time frame: Up to 2 days from enrolment
Incidence of Device Deficiencies
Frequency and type of device deficiencies (malfunctions, usability issues, or inadequacy of instructions for use) observed during the trial.
Time frame: Up to 2 days from enrolment
Plan to share: Yes — De-identified individual participant data (IPD) underlying the results of this trial (including baseline characteristics, outcome measures, and safety data) will be made available to other researchers upon reasonable request, following publication of the main trial results. Data will be shared through a controlled access process after approval of a research proposal and data sharing agreement. Supporting documents (such as the study protocol and statistical analysis plan) will also be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: De-identified IPD will be available beginning 12 months after publication of the primary results and for a period of up to 5 years thereafter.
Access criteria: Researchers must submit a methodologically sound proposal, which will be reviewed by the sponsor and chief investigator. Access will be granted only after a data sharing agreement is signed.
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in May 2026, 10 months.
Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 10 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.